In Regard to Qi et  al

We have read with interest the article by Qi et  al describing the results of a randomized trial testing 66 Gy versus 72 Gy for postoperative radiation therapy (RT) for prostate cancer with pathologic high-risk features (adjuvant RT) or biochemically recurrent prostate cancer patients after radical prostatectomy (salvage RT).1
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comments Source Type: research

Related Links:

18F-labeled prostate-specific membrane antigen (PSMA) PET tracers are increasingly used in preference to 68Ga-PSMA-11 for restaging biochemical recurrence (BCR) of prostate cancer. They are associated with longer half-lives, larger-scale production, and lower positron range than their 68Ga-labeled counterparts. Here, we describe the efficacy of an 18F-labeled radiohybrid PSMA, rhPSMA-7, a novel theranostic PSMA-targeting agent for imaging BCR of prostate cancer. Methods: Datasets from 261 consecutive patients with noncastrate BCR after radical prostatectomy who underwent 18F-rhPSMA-7 PET/CT at our institution between June ...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research
In 2019, approximately 174,650 men will be diagnosed with prostate cancer in the United States.[1] Recent estimates have demonstrated that number to be more than twofold higher in Europe.[2] The Prostate Testing for Cancer and Treatment (ProtecT) trial suggested that conventionally fractionated radiation therapy (CFRT) (1.8-2 Gy, 5 days per week, for 8-9 weeks to a total dose of 70-81 Gy) offers similar oncologic outcomes with improved quality of life when compared to radical prostatectomy.[3,4] Projections indicate that more than one third of men with localized cancer of the prostate in the United States receive some form...
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
In the early 1990 ’s, the increasingly widespread use of prostate-specific antigen as a screening test resulted in an impressive “spike” in the incidence of prostate cancer, unprecedented in the history of oncology. Men with clinically localized cancers facing treatment generally had to decide among radical pro statectomy, external beam radiation therapy, and some form of expectant management. Our group had documented that rates of radical prostatectomy among Medicare beneficiaries increased fivefold between 1984 and 1990.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
AbstractDefinitive therapy for prostate cancer includes radical prostatectomy and radiation therapy. Treatment is elected based on patient preference, biological tumor factors, and underlying health. Post prostatectomy, men are surveyed for disease recurrence with serial PSA measurements, digital rectal exam, and imaging studies depending on nomogram predicted risk of local disease recurrence and distant metastasis. In men with rising PSA levels, pathologically incomplete surgical margins or, if symptoms of metastasis develop, imaging may be obtained to localize disease. In cases of known biochemical recurrence, imaging is...
Source: Abdominal Imaging - Category: Radiology Source Type: research
Background: Dipeptidyl peptidase-4 (DPP4), a cell surface protein, exhibits a crucial role in tumor biology and regulation of the immune system. We aim to study the impact of DPP4 inhibitors (DPP4i) in patients with prostate cancer (PRC), pancreatic cancer (PC) and breast cancer (BC).Methods: Using the SEER and Medicare linked database, we identified patients with PRC or PC or BC with coexisting type II diabetes mellitus between 2007 and 2015. Patients were classified into four groups: (1) not on either DPP4i or metformin (reference group), this group included patient that were on anti-diabetic agents other than metformin ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract PURPOSE: To compare local/metastatic disease progression and overall mortality rates in men with node-negative prostate cancer at radical prostatectomy (RP) that experience biochemical recurrence vs. persistence postoperatively and undergo salvage radiation therapy (sRT). MATERIALS AND METHODS: Data on 760 men who participated in the RTOG 9601 trial were extracted using the NCTN data archive platform. Patients were stratified into biochemical recurrence (nadir-PSA ≤0.4 ng/ml) or persistence (nadir-PSA>0.4 ng/ml) groups, based on the cut-off reported in the original trial. Inverse probability of...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
Authors: Motterle G, Morlacco A, Zattoni F, Karnes RJ Abstract Introduction: Adverse pathological features at radical prostatectomy such as extracapsular extension, seminal-vesicle involvement, positive surgical margins and/or lymph node invasion define a particular subgroup of patients that might benefit from additional treatment after surgery, in particular radiation therapy.Areas covered: Post-prostatectomy radiation is intended as adjuvant, early-salvage or salvage depending on the timing and PSA levels at the treatment. After providing the most used definitions, the high-level evidence supporting adjuvant radi...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
A web-based tool can help predict functional outcomes for five years after treatment of localized prostate cancer with radical prostatectomy (RP), intensity-modulated radiation therapy (RT), or active surveillance, researchers say.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news
Prostate cancer therapies are improving over time. But how do the long-term side effects from the various options available today compare? Results from a newly published study are providing some valuable insights. Investigators at Vanderbilt University and the University of Texas MD Anderson Cancer Center spent five years tracking the sexual, bowel, urinary, and hormonal status of nearly 2,000 men after they had been treated for prostate cancer, or monitored with active surveillance (which entails checking the tumor periodically and treating it only if it begins to grow). Cancers in all the men were still confined to the p...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Prostate Knowledge Treatments HPK Source Type: blogs
ConclusionsFunctional outcomes after treatment for localized prostate cancer can be predicted at the time of diagnosis based on age, race, PSA, biopsy grade, baseline function, and a general question regarding overall health. Providers and patients can use this prediction tool to inform shared decision making.Patient summaryIn this report, we studied patient-reported sexual, urinary, hormonal, and bowel function through 5 yr after treatment with radical prostatectomy, radiation therapy, or active surveillance for localized prostate cancer. We developed a web-based predictive tool that can be used to predict one’s o...
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Physics | Prostate Cancer | Prostatectomy | Radiation Therapy | Radiology